U.S. Entertainment Stock News

Wondering whether Travere Therapeutics at around US$44.12 is still offering value or if the easy gains are already behind it? This article unpacks what the current price really implies. The stock has shown strong share price moves, with returns of 8.9% over 7 days, 40.4% over 30 days, 11.6% year to date, 108.6% over 1 year, 162.6% over 3 years and 120.5% over 5 years. This naturally raises questions about both upside potential and risk. Recent headlines around Travere Therapeutics have...

Synchrony and Lowe's Companies have expanded their partnership with the launch of the MyLowe's Pro Rewards American Express Card. The new co branded card extends purchasing power and rewards for professional customers beyond Lowe's stores to any location where American Express is accepted. The offering targets small to medium business customers within Lowe's Pro segment, with a focus on broader rewards and financing flexibility. Lowe's Companies, NYSE:LOW, is trading at $233.33, with the...

Bristol-Myers Squibb (BMY) opened 2026 with Q1 revenue of US$11.5b, basic EPS of US$1.31 and net income of US$2.7b, setting the tone for how investors will judge its recent profitability. The company has seen quarterly revenue move from US$11.2b and basic EPS of US$1.21 in Q1 2025 to US$11.5b and US$1.31 in Q1 2026. Trailing twelve month EPS reached US$3.57, giving a clearer read on earnings power over the last year. With trailing net profit margin at 15% and recent earnings growth of 34.2%...

Eastman Chemical Q1 2026 earnings: headline numbers in focus Eastman Chemical (EMN) has opened 2026 with Q1 revenue of US$2.2b and basic EPS of US$0.94, setting the stage for how investors assess the latest move in profitability. Over recent quarters the company has seen revenue move between US$2.0b and US$2.3b, with basic EPS ranging from US$0.41 to US$2.85, while trailing twelve month EPS sits at US$3.49 on revenue of US$8.6b. With the stock at US$77.53 and trailing net margin at 4.6%...

T. Rowe Price Group (TROW) opened 2026 with Q1 revenue of US$1.9 billion and basic EPS of US$2.23, alongside trailing twelve month revenue of US$7.4 billion and EPS of US$9.34 that sit against modest 1.9% annual revenue growth and a 27.6% net profit margin over the past year. Over recent quarters, revenue has ranged from US$1.7 billion to US$1.9 billion, while quarterly EPS has moved between roughly US$1.93 and US$2.88. This provides a consistent picture of earnings power, even as the five...

Smokey Bones, the barbecue chain originally founded by Darden Restaurants, has been fully closed after a 27 year run. The shutdown ends a long standing brand legacy that traces back to Darden’s earlier expansion in American casual dining. Although Darden no longer owns Smokey Bones, the closure adds context for investors tracking NYSE:DRI and the broader barbecue and casual dining space. Darden Restaurants, trading as NYSE:DRI, is coming off a mixed share performance backdrop, with the...

If you are wondering whether Kimco Realty's current share price lines up with its underlying value, this article walks through the key numbers so you can judge that for yourself. Over recent periods the stock has seen mixed returns, with a 1.3% decline over the last 7 days, a 4.1% gain over 30 days, 16.6% year to date, 16.0% over 1 year, 43.7% over 3 years and 35.3% over 5 years. Recent coverage of Kimco Realty has focused on its role as a large retail REIT and how investors are weighing...

Neurocrine Biosciences (NasdaqGS:NBIX) reported new two‑year Phase 3 data from its CAHtalyst Pediatric and Adult trials of CRENESSITY in classic congenital adrenal hyperplasia. The peer‑reviewed results cover both children and adults and highlight durable efficacy alongside physiologic glucocorticoid dosing. Data show sustained reductions in harmful steroid exposure and clinical improvements, including better body mass index and insulin resistance in pediatric patients. These findings...

BioNTech, NasdaqGS:BNTX, faces potential U.S. pharmaceutical tariffs that could affect access to a key market. The company is preparing for the announced departures of its co founders from leadership roles. These developments arrive while the share price stands at $97.54 and recent returns show mixed performance across different time frames. For investors watching NasdaqGS:BNTX, these leadership changes and tariff risks are landing on a share price of $97.54, with recent moves including a...

Semtech (SMTC) is back in focus after analysts highlighted its recent track record of exceeding earnings estimates and a current positive Earnings ESP, with supportive ratings indicating firm expectations for its upcoming results. See our latest analysis for Semtech. At a share price of $107.81, Semtech has seen a 30 day share price return of 34.7% and a year to date share price return of 43.25%. Its 1 year total shareholder return of 215.88% and 3 year total shareholder return of close to 5x...

CCC Intelligent Solutions Holdings launched mobile invoice scanning in the CCC ONE platform, integrating directly into its repair management workflow. The new feature uses AI to match invoice line items to repair orders, automating parts reconciliation for repair shops. The capability is available at no additional cost to users of CCC ONE, aiming to cut manual data entry and reduce processing time. CCC Intelligent Solutions Holdings, traded as NasdaqGS:CCC, is rolling out this product...

If you are wondering whether Teradata is attractively priced or looking stretched at its current levels, you will want to understand what the valuation numbers are actually saying. The stock last closed at US$27.96, with returns of 5.8% over the past week, 10.8% over the past month, a 5.8% decline year to date, and 26.7% over the last year, alongside weaker 3 year and 5 year returns of 37.2% and 31.0% respectively. These mixed returns have kept Teradata on the radar for investors who pay...

In April 2026, Park National Corporation reported first-quarter 2026 results showing higher net interest income of US$125.78 million but slightly lower net income of US$41.69 million and earnings per share, alongside a quarterly dividend declaration of US$1.10 per share. The quarter also featured a rise in net charge-offs to US$2.63 million from US$592,000 a year earlier, putting asset quality trends in sharper focus for investors. We’ll now look at how the mix of rising net interest income...

In April 2026, Agree Realty Corporation completed roughly US$1.00 billion of follow-on common equity offerings and filed an additional US$1.75 billion at-the-market equity program alongside a new universal shelf registration covering common and preferred stock, depositary shares, warrants, and debt securities. This combination of fresh equity capital and expanded shelf capacity signals that Agree Realty is preparing for a potentially larger, more flexible funding toolkit to support its...

Garmin (NYSE:GRMN) reports record Q1 2026 revenue and operating income, setting new highs for the company. Fitness segment revenue rises 42% in Q1 2026, supported by advanced wearables and recent product launches. Garmin plans around 100 product launches in 2026 across its diversified segments. The company secures multiple new EASA certifications for aviation equipment, expanding its presence in the European market. For investors tracking consumer electronics and aerospace, Garmin sits at...

Banco Latinoamericano de Comercio Exterior S. A. gained shareholder approval at its recent Annual Shareholders' Meeting to change its legal name to Bladex Inc. The rebranding will shift the company’s official identity while it continues to trade on the NYSE under ticker NYSE:BLX. The name change is expected to influence how the bank presents itself to clients, investors, and counterparties across Latin America and beyond. The rebrand to Bladex Inc. comes at a time when NYSE:BLX shares are...

NovoCure (NasdaqGS:NVCR) received FDA approval for Optune Pax for locally advanced pancreatic cancer and has started its U.S. commercial launch. The new therapy has seen early adoption and payer coverage in the U.S., expanding NovoCure's reach beyond its original focus in glioblastoma. Pivotal Phase 3 data from the TRIDENT trial in newly diagnosed glioblastoma are expected later this year. NovoCure focuses on tumor treating fields therapy, a medical technology designed to disrupt cancer...

Ocular Therapeutix recently enrolled the first patient in its SOL-X long-term extension trial of AXPAXLI (OTX-TKI) for wet age-related macular degeneration, a 36‑month open-label study designed to assess long-term safety, efficacy, and disease-modifying potential following completion of the SOL-1 or SOL-R trials. This extension study is intended to test whether earlier and sustained AXPAXLI therapy can reduce fibrosis, macular atrophy, and treatment burden compared with pulsatile anti-VEGF...

MasTec (MTZ) opened Q1 2026 with revenue of about US$3.8b and basic EPS of US$0.78, setting the tone for how the rest of the year may shape up on both the top and bottom line. Over the past six reported quarters, revenue has moved from US$3.4b in Q4 2024 to just under US$4.0b in Q3 2025 before landing at US$3.8b in the latest quarter. Quarterly basic EPS has ranged from US$0.13 in Q1 2025 to US$2.07 in Q3 2025 and stands at US$0.78 in Q1 2026. With trailing twelve month net income of...

Antero Resources reported past first-quarter 2026 results with revenue of US$1,945.13 million, net income of US$535.22 million, and record production of 3,852 MMcfe/d, alongside sharply lower property and equipment impairment charges. The company also reaffirmed its 2026 production guidance while highlighting ahead-of-schedule integration of the HG acquisition, which is already contributing to higher volumes and operational efficiencies. We’ll now examine how this record quarterly...

If you are wondering whether Rubrik's current share price reflects its true worth, this breakdown will help you connect the recent moves in the stock to what the underlying valuation signals are saying. Rubrik last closed at US$55.07, with returns of 5.3% over the past week and 13.3% over the past month, while the 1 year return sits at a 24.9% decline. Recent trading interest has been influenced by ongoing attention on data security and cloud software providers, as investors reassess how...

American Water Works Company (NYSE:AWK) has announced a proposed merger with Essential Utilities to create a large regulated U.S. water and wastewater utility. The combined business would bring together regulated water and wastewater operations across multiple states, subject to regulatory and shareholder approvals. The companies plan to integrate networks and services to serve a wider customer base under a unified regulated utility structure. For investors watching NYSE:AWK, this update...

If you are asking whether Enterprise Products Partners is still reasonably priced after a long run in the unit price, this article walks through what the current valuation really reflects and where the key pressure points are. The units last closed at US$38.03, with stated returns of 0.1% over 7 days, 1.6% over 30 days, 18.3% year to date, 33.3% over 1 year, 83.1% over 3 years and 134.3% over 5 years, which gives plenty of context for a closer look at value. Recent coverage has focused on...

If you are wondering whether Tenet Healthcare at a recent close of US$183.27 still offers value or is looking stretched, the numbers behind the share price can help frame that decision. The stock has returned 1.4% over the last 7 days, while the 30 day and year to date returns of 3.7% decline and 8.1% decline sit alongside a 23.8% return over the last year and 164.3% over 3 years. Recent coverage has focused on Tenet Healthcare's position in the US hospital and healthcare services space,...